From Eliot Forster, MedCity’s Executive Chair
In the month since our last newsletter, we have heard the Government’s Spending Review and Autumn Statement. Likely to impact every part of our sector from basic research to big business, the funding priorities outlined so far are only top line and of course the devil will be in the detail. You can see our response to the statement so far below – I would be interested to hear your views.
On a more celebratory note, I’m delighted to let you know that MedCity has a new CEO in the form of Sarah Haywood, who has been steering the ship with great energy and success as COO. The new job title is a well-deserved recognition of the responsibility of her role, and I’m very pleased to be able to share the news with you.
December is still far from over and we have a full January to look forward to, including some major activities in partnership with the London Stock Exchange. Intro with Eliot for approval – to be added